WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406733
CAS#: 848354-66-5
Description: NCH-51, also known as PTACH, is a histone deacetylase (HDAC) inhibitor. NCH-51 tnhibits growth of various cancer cells in vitro (EC50 = 1.1 - 9.1 μM). NCH-51 could inhibit the cell growth of a variety of lymphoid malignant cells through apoptosis induction, more effectively than SAHA. NCH-51 upregulated anti-oxidant molecules including peroxiredoxin 1 and 2 and glutathione S-transferase at the protein level. NCH-51 exhibits cytotoxicity by sustaining ROS at the higher level greater than SAHA.
Hodoodo Cat#: H406733
Name: NCH-51
CAS#: 848354-66-5
Chemical Formula: C20H26N2O2S2
Exact Mass: 390.14
Molecular Weight: 390.560
Elemental Analysis: C, 61.51; H, 6.71; N, 7.17; O, 8.19; S, 16.42
Synonym: NCH-51; NCH 51; NCH51. PTACH
IUPAC/Chemical Name: S-(7-oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate
InChi Key: MDYDGUOQFUQOGE-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23)
SMILES Code: CC(C)C(SCCCCCCC(NC1=NC(C2=CC=CC=C2)=CS1)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 390.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Nageshappa S, Carromeu C, Trujillo CA, Mesci P, Espuny-Camacho I, Pasciuto E,
Vanderhaeghen P, Verfaillie CM, Raitano S, Kumar A, Carvalho CM, Bagni C, Ramocki
MB, Araujo BH, Torres LB, Lupski JR, Van Esch H, Muotri AR. Altered neuronal
network and rescue in a human MECP2 duplication model. Mol Psychiatry. 2016
Feb;21(2):178-88. doi: 10.1038/mp.2015.128. Epub 2015 Sep 8. PubMed PMID:
26347316; PubMed Central PMCID: PMC4720528.
2: Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N,
Ochiai K, Okamoto T. Novel histone deacetylase inhibitor NCH-51 activates latent
HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. doi:
10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12. PubMed PMID: 21402072.
3: Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T,
Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth
inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid
malignant cells. Leukemia. 2007 Nov;21(11):2344-53. Epub 2007 Aug 9. PubMed PMID:
17690692.
4: Suzuki T, Hisakawa S, Itoh Y, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.
Identification of a potent and stable antiproliferative agent by the prodrug
formation of a thiolate histone deacetylase inhibitor. Bioorg Med Chem Lett. 2007
Mar 15;17(6):1558-61. Epub 2007 Jan 13. PubMed PMID: 17257837.
